Cathie Wood-Led Ark Invest Continues Shopping For Shopify Stock, Sells $15M Worth Of Jack Dorsey's Block Shares Amid Bitcoin Price Drop
On Tuesday, Cathie Wood's Ark Invest made some significant trades, notably buying shares of Shopify Inc (NYSE:SHOP) and selling off Block Inc (NYSE:SQ) stocks.The Shopify TradeArk Invest's ETFs, inclu
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : Morgan Stanley Cuts Target Price to $57.00 From $85.00
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Intellia Therapeutics Is Maintained at Neutral by Citigroup
Intellia Therapeutics Is Maintained at Neutral by Citigroup
Express News | Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript
Intellia Therapeutics Q1 2024 Earnings: Aligns With Analyst Projections Amidst Strategic Advances
Intellia Therapeutics Is Maintained at Outperform by BMO Capital
Intellia Therapeutics Is Maintained at Outperform by BMO Capital
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 188.07% BMO Capital $62 → $70 Maintains Outperform 04/23/2024 19.34% Wedbush → $29 Reiterates N
Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : BMO Raises Target Price to $70.00 From $62.00
Express News | Intellia Therapeutics Inc : Guggenheim Cuts Target Price to $55 From $64
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : Raymond James Raises Target Price to $58 From $57
Express News | Intellia Therapeutics Inc : Leerink Partners Cuts Target Price to $70 From $71
Intellia Therapeutics | 10-Q: Quarterly report